The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted Therapy

EGFR mutations represent the most common currently targetable oncogenic driver in non-small cell lung cancer. There has been tremendous progress in targeting this alteration over the course of the last decade, and third generation tyrosine kinase inhibitors offer previously unseen survival rates amo...

Descripción completa

Detalles Bibliográficos
Autores principales: Friedlaender, Alex, Tsantoulis, Petros, Chevallier, Mathieu, De Vito, Claudio, Addeo, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044828/
https://www.ncbi.nlm.nih.gov/pubmed/33869038
http://dx.doi.org/10.3389/fonc.2021.644472

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044828/
https://www.ncbi.nlm.nih.gov/pubmed/33869038
http://dx.doi.org/10.3389/fonc.2021.644472

Ejemplares similares